Clinical Trial Detail

NCT ID NCT03215706
Title A Study of Nivolumab and Ipilimumab Combined With Chemotherapy Compared to Chemotherapy Alone in First Line NSCLC (CheckMate 9LA)
Recruitment Active, not recruiting
Gender both
Phase Phase III
Variant Requirements Yes
Sponsors Bristol-Myers Squibb
Indications

lung non-small cell carcinoma

lung squamous cell carcinoma

Therapies

Carboplatin + Cisplatin + Paclitaxel + Pemetrexed Disodium

Ipilimumab + Nivolumab

Age Groups: adult senior

Additional content available in CKB BOOST